In Episode 35, the second in a three-part Conversations in Nephrology series on IgA nephropathy (IgAN), host Brad Rovin, MD (The Ohio State University), KDIGO IgAN/IgAV Guideline Co-Chair, is joined by Andrew Bomback, MD (Columbia University Irving Medical Center), to explore which patients may benefit from complement inhibition and what information could help guide treatment selection.
Dr. Rovin and Dr. Bomback examine how kidney biopsy findings, genetic testing, and emerging complement biomarkers may inform an individualized approach to IgAN care. Drawing on experience with complement inhibition in C3 glomerulopathy, they also discuss practical treatment considerations, including vaccination, antibiotic prophylaxis, and multidisciplinary care, as well as key questions for future research.
The series concludes with an upcoming episode featuring Sayna Norouzi, MD (Loma Linda University Medical Center), on where complement inhibitors fit within the IgAN therapeutic toolbox.
This episode was supported by Alexion.